H. Lundbeck A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public, Subsidiary
- Established
- 2000-01-01
- Employees
- 5.6K
- Market Cap
- -
- Website
- http://www.lundbeck.com
Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-10-06
- Last Posted Date
- 2010-09-29
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 35
- Registration Number
- NCT00766870
- Locations
- 🇨🇦
CA009, Mississauga, Ontario, Canada
Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia
- First Posted Date
- 2008-10-01
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 18
- Registration Number
- NCT00763438
- Locations
- 🇫🇷
FR002, Allonnes, France
Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 74
- Registration Number
- NCT00761306
Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 250
- Registration Number
- NCT00759460
- Locations
- 🇨🇳
CN002, Beijing, China
Exploratory Cognition Study of Sertindole in Patients With Schizophrenia
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 96
- Registration Number
- NCT00759421
- Locations
- 🇨🇳
TWN001, Tapei, Taiwan
Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2010-09-27
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 16
- Registration Number
- NCT00756249
- Locations
- 🇫🇷
FR002, Paris, France
🇫🇮FI004, Helsinki, Finland
🇬🇧GB001, Glasgow, United Kingdom
Efficacy of Bifeprunox in Patients With Schizophrenia
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2010-09-27
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 346
- Registration Number
- NCT00704509
- Locations
- 🇮🇳
IN006, Chennai, India
🇮🇳IN008, Ahmedabad, India
🇮🇳IN011, Ahmedabad, India
Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2014-04-01
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 535
- Registration Number
- NCT00694304
Efficacy of Bifeprunox in Patients With Schizophrenia
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2010-09-27
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 227
- Registration Number
- NCT00658645
- Locations
- 🇷🇺
RU017, Chita, Russian Federation
🇷🇺RU005, Moscow, Russian Federation
🇷🇴RO002, Bucuresti, Romania
Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 264
- Registration Number
- NCT00654706
- Locations
- 🇺🇸
US012, Baltimore, Maryland, United States
🇺🇸US020, Dallas, Texas, United States
🇺🇸US014, Stanford, California, United States
© Copyright 2024. All Rights Reserved by MedPath